A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre, phase III clinical study to evaluate the immunogenicity and safety of Inactivated Influenza vaccine (split virion) I.P. (Tetravalent) of M/s Cadila Healthcare Limited in healthy children aged 6 months to 17 years
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Zydus Lifesciences
- 13 Dec 2017 New trial record